smscall
logo
Pharma & Healthcare

Published On: Sep 26, 2025

Global Veterinary Lyme Disease Vaccines Industry Growth and Trends Forecast to 2031

  • starstarstarstarstar
  • 0
  • 0 Reviews
  • 97 Pages
  • 0 Views

Version Type

$3,450.00

Summary
According to APO Research, the global veterinary Lyme vaccines market reached USD 147.1 million in 2024 on 6.42 million doses and is projected to reach USD 210.6 million by 2031 on 8.42 million doses (2025–2031 CAGR 5.6%, volume-led with moderating ASPs). North America supplied 88.2% of 2024 revenue and remains the growth anchor to USD 188.7 million by 2031, while Europe advances to USD 20.4 million. Recombinant subunits increase their revenue mix from 54.5% to 57.8% by 2031 as practices standardize clear claims and annual revaccination; bacterins persist in price-sensitive channels. Vendor concentration remains high: Zoetis + Boehringer Ingelheim + Elanco ≈ 83.5% of revenue in 2024, followed by Merck Animal Health and Bioveta.
Veterinary Lyme disease vaccines are companion-animal biologics used to reduce the probability and magnitude of infection with Borrelia burgdorferi sensu lato after exposure to competent Ixodes ticks. Clinical use is functionally canine; feline products exist only at marginal scale. Vaccination is risk-based and paired with acaricides and environmental tick management. Lyme-borreliae are host-adapted spirochetes maintained in enzootic cycles linking small mammals and certain birds with hard ticks; larvae and nymphs acquire organisms during a blood meal, retain them transstadially, and transmit during subsequent feedings. Upon tick attachment, vector-adapted gene programs down-shift while mammalian-phase genes up-regulate to enable migration from the midgut to salivary glands. Geographies mirror vector belts: I. scapularis (Northeast/Upper Midwest US), I. pacificus (US West Coast), I. ricinus (Europe), and I. persulcatus (northern Eurasia). North American canine disease is dominated by B. burgdorferi sensu stricto; B. garinii and B. afzelii contribute in Europe and the UK.
From a market and regulatory standpoint, only North America and Europe provide contiguous Ixodes ranges, clear biologics pathways, and stable clinical demand—conditions required for licensed products and defensible sizing. Accordingly, this report quantifies these two regions and treats Asia, South America, and Africa qualitatively to avoid over-extrapolating from heterogeneous, low-signal data.
Market size and drivers. The global Veterinary Lyme Disease Vaccines market was USD147.12 million in 2024, rising from USD116.65 million in 2020 (CAGR 5.97%). It is projected to reach USD210.61 million by 2031 (2025–2031 CAGR 5.57%), driven by volume growth (global doses 6.42→8.42 million, 2020→2031; 2025–2031 CAGR 3.79%) while price growth moderates (ASP USD22.92/dose in 2024 easing to USD22.60 in 2025, then trending toward USD25.02 by 2031). Mix shift favors recombinant subunit vaccines, which accounted for USD80.24 million (54.5%) of 2024 revenue and are expected to reach USD121.71 million (57.8%) by 2031; bacterins remain relevant in price-sensitive channels.
Regional structure. North America represented USD129.68 million (88.15%) in 2024 and is forecast to USD188.72 million by 2031 (CAGR 5.83%), sustained by high I. scapularis/pacificus prevalence, established canine vaccination norms, and specialty distribution. Europe was USD16.35 million (11.11%) in 2024, projected to USD20.39 million by 2031 (CAGR 3.34%); demand is concentrated in Poland, Germany, France, Sweden, Finland, the UK, and Romania, consistent with I. ricinus/persulcatus belts.
Competitor landscape. Based on 2024 reported volumes and realized ASPs, the leading manufacturers are Zoetis (USD50.32m), Boehringer Ingelheim (USD46.02m), Elanco (USD26.44m), Merck Animal Health (USD20.95m), and Bioveta (USD3.39m). The top three account for ~83.5% of global revenue, reflecting scale advantages in R&D, licensure, and North American commercial reach.
Figures reflect bottom-up reconciliation of company-level doses and net pricing to regional totals; feline usage is retained in totals but remains de minimis. The 2025 ASP dip is attributed to contract resets and channel mix (bacterin share/chain discounting), not to structural price erosion.
Veterinary Lyme disease vaccines are companion-animal biologics designed to reduce the probability and magnitude of infection with Borreliella (Borrelia) burgdorferi sensu lato after exposure to competent Ixodes ticks. The commercial and clinical category is functionally canine; a limited feline line exists in parts of Europe, and there are no licensed equine or food-animal products. Use is risk-based rather than core and is paired with acaricides and environmental tick management. The etiologic agents are host-adapted spirochetes maintained in an enzootic cycle linking small mammals and certain birds with hard ticks. Larval and nymphal Ixodes acquire organisms during a blood meal, retain them transstadially, and transmit during subsequent feeding. Within unfed ticks, spirochetes occupy a vector-adapted state; attachment and feeding trigger a transcriptional switch toward mammalian-phase biology, down-regulating vector-phase genes and up-regulating mammalian-phase genes as organisms exit the midgut for the salivary glands. Geographically, veterinary and human hotspots mirror vector ranges: I. scapularis in the northeastern and upper midwestern United States with a coastal Pacific belt under I. pacificus; I. ricinus across temperate Europe; and I. persulcatus across northern Eurasia. North American canine disease is dominated by B. burgdorferi sensu stricto, whereas B. garinii and B. afzelii contribute materially in Europe and the UK; stable natural foci also occur across parts of northeastern Asia.
Two vaccine platforms encompass licensed products and map onto distinct biological bottlenecks. Bacterins are inactivated whole-cell preparations that present broad antigenic repertoires; in commerce they are typically bivalent by strain in North America and trivalent in Europe to align with regional sensu lato diversity. Recombinant protein subunits are defined-composition formulations built around outer-surface lipoproteins with established protective correlates. One branch uses lipidated outer surface protein A (OspA) as a single antigen; the other pairs OspA with an engineered OspC chimeric epitope protein (“chimeritope”) that concatenates linear epitopes from multiple OspC types to extend breadth. Mechanistically, anti-OspA antibodies act mainly within the feeding tick midgut, binding OspA on vector-phase organisms and impeding survival and transmission, whereas anti-OspC antibodies act in the early mammalian window at the bite site and draining tissues, promoting neutralization and opsonophagocytic clearance before hematogenous dissemination. The responses are temporally complementary and address distinct transmission bottlenecks.
Antigen-level detail underpins both design and diagnostics. OspA is a lipidated outer-membrane lipoprotein abundantly expressed by unfed tick-phase organisms; protective B-cell epitopes cluster toward the C-terminal domain, the locus of canonical neutralizing monoclonals, and OspA is down-regulated during feeding and host entry, which explains its principal value at the vector interface and its pairing with mammalian-phase antigens in some subunits. OspC is a smaller, dimeric lipoprotein whose transcription is strongly induced during tick feeding and the first days of mammalian infection; it contributes to early tissue invasion and complement interactions and is a dominant target of early humoral responses. OspC is highly polymorphic and partitioned into dozens of phylogenetic types maintained by recombination and frequency-dependent selection; antibody responses are largely type-specific and cross-protection is limited. Chimeritope designs address this constraint by assembling immunodominant linear segments—classically from the variable L5 and H5 regions—drawn from representative OspC types into a single recombinant antigen capable of broad binding across OspC diversity. In genomic context, OspA is encoded on lp54, OspC on cp26, and the vls cassette system on lp28-1 underpins antigenic variation during persistence; this plasmid architecture explains phase-specific expression and immune evasion. Serology follows from these rules: antibodies to the VlsE-derived C6 peptide track natural infection and are not induced by OspA-only vaccination, whereas bacterins and OspC-containing subunits broaden antibody profiles and require assay selection and clinical correlation to distinguish vaccine responses from infection.
Historically, the category progressed from whole-cell to defined-antigen formulations. Early licensed canine products in the 1990s were formalin-inactivated cell-lysate bacterins (e.g., LymeVax and Galaxy Lyme). The next phase introduced recombinant OspA subunits to avoid nonessential antigens and focus on vector-phase blockade. From the mid-2010s, OspA plus OspC chimeritope formulations appeared, targeting both the tick midgut and the early mammalian phase while addressing OspC's strong polymorphism. This trajectory reflects a shift from breadth via whole-cell antigen overload to breadth-with-specificity via defined antigens, with corresponding gains in compositional clarity and mechanistic alignment to transmission biology.
The global burden aligns with vector ecology and surveillance intensity. In the United States, highest veterinary and human risk occurs from the mid-Atlantic through New England and the upper Midwest, with additional foci on the Pacific coast; in Canada, risk concentrates in southern Ontario, Québec, the Maritimes, and expanding prairie and coastal belts. In Europe, risk spans the UK and Ireland, the Benelux and Alpine corridors, Germany and Poland, the Baltics and Scandinavia, and northern Mediterranean foothills where I. ricinus is established. Across northern Eurasia, I. persulcatus supports foci from northeastern Europe through western Russia into Siberia and parts of the Far East. Outside North America and Europe many jurisdictions do not license canine Lyme vaccines and rely on acaricides and exposure management.
Current products in commerce resolve to a short, well-defined list whose differences are meaningful at the level of antigen strategy, breadth, and evidentiary posture rather than dose logistics. VANGUARD® crLyme is an OspA plus OspC chimeritope subunit; the OspC component presents a panel of linear epitopes drawn from diverse OspC types, aiming to maintain binding breadth across local OspC ecologies while pairing vector-phase interception with early mammalian-phase neutralization. This defined-composition approach yields strong titers to both components, challenge-model protection across infection and histopathology endpoints, and an extended duration-of-immunity label in its home market; trade-offs include broader serologic footprints that can complicate interpretation on certain assays and a dependence on epitope selection relative to regional OspC phylogeny.
RECOMBITEK® Lyme (rLyme) is a non-adjuvanted, lipidated OspA subunit that emphasizes a tight antigen profile and a vector-interface mechanism; benefits include minimal extraneous proteins and preserved interpretability of C6-based diagnostics, while constraints center on the absence of an explicit OspC component, making timely transmission interception and booster maintenance central to performance. Nobivac® Lyme is a bivalent bacterin built around two B. burgdorferi sensu stricto strains selected to emphasize OspA and OspC expression characteristics; it delivers broad borreliacidal responses with long field experience and a 12-month duration label in its home market, balanced against the inherent complexity of whole-cell formulations and limited public standardization of OspC expression in production cultures. Duramune® Lyme and Ultra Duramune® Lyme—and their successor branding TruCan™ Lyme and TruCan™ Ultra Lyme—are bivalent bacterins positioned for breadth and for integration into combination presentations with Leptospira or broader canine cores; strengths include robust whole-cell immunogenic breadth and portfolio flexibility, while constraints mirror the bacterin class: extraneous-antigen overhead, culture-stage expression variability, and the fact that reduced fill volume by itself does not evidence superior protection. In Europe and the UK, Borrelym 3 and Merilym 3 are trivalent bacterins that include B. afzelii, B. garinii, and B. burgdorferi sensu stricto to match regional sensu lato diversity; they are well aligned to I. ricinus regions but, as whole-cell products, share the class’s compositional constraints and have limited public species-specific protection data versus each included sensu lato species. Within the same manufacturer’s portfolio, Biocan B is a canine bacterin used where national registrations permit, and Biofel B is a niche feline bacterin available in limited jurisdictions; both follow the bacterin paradigm with corresponding advantages in breadth and constraints in specificity and transparency.
Taken together, veterinary Lyme disease vaccines are best understood as a small, mechanism-anchored category defined by two platforms, two principal antigens with distinct temporal loci of action, and a finite set of market models whose antigen strategies map directly onto transmission biology. Bacterins trade compositional complexity for breadth; OspA subunits trade breadth for precision at the vector interface; OspA plus OspC chimeritopes aim to recapture breadth with defined antigens by spanning vector and early mammalian phases. Regional epidemiology and OspC phylogeny shape optimal fit, diagnostics must be interpreted with platform awareness, and program value is maximized when vaccination is integrated with acaricides and exposure management in dogs genuinely at risk.
Report Scope (at a glance)
Licensed companion-animal Lyme vaccines only: canine and feline where approved; recombinant-subunit (incl. OspA±chimeric OspC) and inactivated bacterins. Excludes stock immunotherapies, tick preventives, and non-vaccine products. Market size = ex-manufacturer net sales: volume (k doses) and revenue (USDmn), nominal USD. History 2020–2024; base 2025; forecast 2026–2031. Segmentation by Type, Company (Zoetis, Boehringer Ingelheim, Elanco, Merck Animal Health, Bioveta; “Others”), and Region/Country (US, Canada; Germany, France, UK/GB+NI, Sweden, Finland, Poland, Denmark, Romania, Rest of Europe; Rest of World where lawfully supplied). Inclusion requires lawful access and measurable volume. Estimates triangulate regulator files, company disclosures, structured interviews, and epidemiology anchors.
Veterinary Lyme Disease Vaccines Segment by Company
Zoetis
Boehringer Ingelheim
Elanco
Merck Animal Health
Bioveta
Veterinary Lyme Disease Vaccines Segment by Type
Recombinant Subunit Vaccines
Bacterin Vaccines
Veterinary Lyme Disease Vaccines Segment by Application
Canine
Feline
Veterinary Lyme Disease Vaccines Segment by Region
North America
United States
Canada
Europe
Germany
Poland
France
Sweden
Finland
United Kingdom (GB/NI)
Romania
Denmark
Rest of Europe
Key Drivers & Barriers
Category growth is demand-led by Ixodes epidemiology, seasonality, and licensure—not channel mechanics—so administered doses track where dogs meet infected ticks and how well clinics complete priming and boosters. North America’s Northeast/Upper Midwest cohorts underpin the economics (≈88.15% of 2024 revenue on ~77% of doses at structurally higher achieved prices), while Europe adds patchy, lower-priced units under bacterin-led authorizations. From 2020 to 2024, value rose from USD116.65M to USD147.12M on price realization (global ASP from USD19.93 to USD22.92) amid flat 2022–2024 volumes; the 2025–2031 outlook pivots to unit-led growth as practices raise series completion within the same Q2–Q3 seasonal gate, taking total administrations from 6.417M in 2024 to 8.417M in 2031 (≈3.79% CAGR) and value to USD210.61M, with price drifting ~1.71% as recombinant subunits expand from 2.995M doses in 2024 to ~4.527M by 2031. Execution beats discounting: maintain uninterrupted legal access, stage inventory into endemic belts ahead of season, align antigen design and evidence with local serotypes, and drive adherence through nurse-led workflows, recalls, and one-touch wellness bundling. Key sensitivities remain tick-season length/intensity, authorization scopes (age, intervals, DoI), supply reliability through the seasonal window, and local risk salience; challenges include spatial heterogeneity, substitution by modern preventives without clear additive messaging, and Europe’s regulatory fragmentation. Sponsors that pair resilient supply with precise geotargeting, stable protocols, and mix discipline capture the modeled value step-up while preserving price integrity.
Reasons to do this study
This study is undertaken to (i) quantify North America and Europe, the only regions with contiguous Ixodes belts and stable regulatory pathways; (ii) explain the 2025 ASP dip as a function of contract resets and channel mix rather than structural erosion; (iii) forecast doses, ASP, and revenue through 2031 by type (recombinant vs bacterin), application (canine, feline—de minimis), and country, anchored to licensed-product availability and practice norms; and (iv) assess competitive positioning and route-to-market implications in a high-concentration industry.
The intended readers are manufacturers (portfolio strategy, capacity and pricing posture), distributors and corporate clinic chains (inventory and contracting), and investors (exposure, sensitivity to mix/price). By stating scope limits (NA/EU quantified; other regions treated qualitatively), methods (company-level dose × realized price reconciliation), and decision questions up front, this report provides an auditable basis for planning rather than a generic market review.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Veterinary Lyme Disease Vaccines manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Veterinary Lyme Disease Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
Table 1:Major Company of Recombinant Subunit Vaccines
Table 2:Major Company of Bacterin Vaccines
Table 3:Global Veterinary Lyme Disease Vaccines Sales by Type (2020 VS 2024 VS 2031) & (US$ Million)
Table 4:Global Veterinary Lyme Disease Vaccines Sales by Type (2020-2025) & (k doses)
Table 5:Global Veterinary Lyme Disease Vaccines Sales Market Share in Volume by Type (2020-2025)
Table 6:Global Veterinary Lyme Disease Vaccines Sales by Type (2020-2025) & (US$ Million)
Table 7:Global Veterinary Lyme Disease Vaccines Sales Market Share in Value by Type (2020-2025)
Table 8:Global Veterinary Lyme Disease Vaccines Price by Type (2020-2025) & (USD/dose)
Table 9:Global Veterinary Lyme Disease Vaccines Sales by Type (2026-2031) & (k doses)
Table 10:Global Veterinary Lyme Disease Vaccines Sales Market Share in Volume by Type (2026-2031)
Table 11:Global Veterinary Lyme Disease Vaccines Sales by Type (2026-2031) & (US$ Million)
Table 12:Global Veterinary Lyme Disease Vaccines Sales Market Share in Value by Type (2026-2031)
Table 13:Global Veterinary Lyme Disease Vaccines Price by Type (2026-2031) & (USD/dose)
Table 14:North America Veterinary Lyme Disease Vaccines Sales by Type (2020-2025) & (k doses)
Table 15:North America Veterinary Lyme Disease Vaccines Sales by Type (2020-2025) & (US$ Million)
Table 16:Europe Veterinary Lyme Disease Vaccines Sales by Type (2020-2025) & (k doses)
Table 17:Europe Veterinary Lyme Disease Vaccines Sales by Type (2020-2025) & (US$ Million)
Table 18:Asia-Pacific Veterinary Lyme Disease Vaccines Sales by Type (2020-2025) & (k doses)
Table 19:Asia-Pacific Veterinary Lyme Disease Vaccines Sales by Type (2020-2025) & (US$ Million)
Table 20:Latin America Veterinary Lyme Disease Vaccines Sales by Type (2020-2025) & (k doses)
Table 21:Latin America Veterinary Lyme Disease Vaccines Sales by Type (2020-2025) & (US$ Million)
Table 22:Middle East and Africa Veterinary Lyme Disease Vaccines Sales by Type (2020-2025) & (k doses)
Table 23:Middle East and Africa Veterinary Lyme Disease Vaccines Sales by Type (2020-2025) & (US$ Million)
Table 24:Veterinary Lyme Disease Vaccines Industry Trends
Table 25:Veterinary Lyme Disease Vaccines Industry Drivers
Table 26:Veterinary Lyme Disease Vaccines Industry Opportunities and Challenges
Table 27:Veterinary Lyme Disease Vaccines Industry Restraints
Table 28:Global Veterinary Lyme Disease Vaccines Sales Revenue by Company (US$ Million) & (2020-2025)
Table 29:Global Veterinary Lyme Disease Vaccines Revenue Market Share by Company (2020-2025)
Table 30:Global Veterinary Lyme Disease Vaccines Sales by Company (2020-2025) & (k doses)
Table 31:Global Veterinary Lyme Disease Vaccines Sales Share by Company (2020-2025)
Table 32:Global Veterinary Lyme Disease Vaccines Market Price by Company (2020-2025) & (USD/dose)
Table 33:Global Veterinary Lyme Disease Vaccines Industry Company Ranking, 2023 VS 2024 VS 2025
Table 34:Global Veterinary Lyme Disease Vaccines Major Company Production Sites and Headquarters
Table 35:Global Veterinary Lyme Disease Vaccines Company, Product Type & Application
Table 36:Global Veterinary Lyme Disease Vaccines Company Establishment Date
Table 37:Global Company Market Concentration Ratio (CR5 and HHI)
Table 38:Global Veterinary Lyme Disease Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
Table 39:Global Veterinary Lyme Disease Vaccines Market Size Comparison by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40:Global Veterinary Lyme Disease Vaccines Sales by Region (2020-2025) & (k doses)
Table 41:Global Veterinary Lyme Disease Vaccines Sales Market Share in Volume by Region (2020-2025)
Table 42:Global Veterinary Lyme Disease Vaccines Sales by Region (2020-2025) & (US$ Million)
Table 43:Global Veterinary Lyme Disease Vaccines Sales Market Share in Value by Region (2020-2025)
Table 44:Global Veterinary Lyme Disease Vaccines Sales (k doses), Value (US$ Million), Price (USD/dose) and Gross Margin (2020-2025)
Table 45:Global Veterinary Lyme Disease Vaccines Sales by Region (2026-2031) & (k doses)
Table 46:Global Veterinary Lyme Disease Vaccines Sales Market Share in Volume by Region (2026-2031)
Table 47:Global Veterinary Lyme Disease Vaccines Sales by Region (2026-2031) & (US$ Million)
Table 48:Global Veterinary Lyme Disease Vaccines Sales Market Share in Value by Region (2026-2031)
Table 49:Global Veterinary Lyme Disease Vaccines Sales (k doses), Value (US$ Million), Price (USD/dose) and Gross Margin (2026-2031)
Table 50:Global Veterinary Lyme Disease Vaccines Sales by Application (2020 VS 2024 VS 2031) & (US$ Million)
Table 51:Global Veterinary Lyme Disease Vaccines Sales by Application (2020-2025) & (k doses)
Table 52:Global Veterinary Lyme Disease Vaccines Sales Market Share in Volume by Application (2020-2025)
Table 53:Global Veterinary Lyme Disease Vaccines Sales by Application (2020-2025) & (US$ Million)
Table 54:Global Veterinary Lyme Disease Vaccines Sales Market Share in Value by Application (2020-2025)
Table 55:Global Veterinary Lyme Disease Vaccines Price by Application (2020-2025) & (USD/dose)
Table 56:Global Veterinary Lyme Disease Vaccines Sales by Application (2026-2031) & (k doses)
Table 57:Global Veterinary Lyme Disease Vaccines Sales Market Share in Volume by Application (2026-2031)
Table 58:Global Veterinary Lyme Disease Vaccines Sales by Application (2026-2031) & (US$ Million)
Table 59:Global Veterinary Lyme Disease Vaccines Sales Market Share in Value by Application (2026-2031)
Table 60:Global Veterinary Lyme Disease Vaccines Price by Application (2026-2031) & (USD/dose)
Table 61:North America Veterinary Lyme Disease Vaccines Sales by Application (2020-2025) & (k doses)
Table 62:North America Veterinary Lyme Disease Vaccines Sales by Application (2020-2025) & (US$ Million)
Table 63:Europe Veterinary Lyme Disease Vaccines Sales by Application (2020-2025) & (k doses)
Table 64:Europe Veterinary Lyme Disease Vaccines Sales by Application (2020-2025) & (US$ Million)
Table 65:Asia-Pacific Veterinary Lyme Disease Vaccines Sales by Application (2020-2025) & (k doses)
Table 66:Asia-Pacific Veterinary Lyme Disease Vaccines Sales by Application (2020-2025) & (US$ Million)
Table 67:Latin America Veterinary Lyme Disease Vaccines Sales by Application (2020-2025) & (k doses)
Table 68:Latin America Veterinary Lyme Disease Vaccines Sales by Application (2020-2025) & (US$ Million)
Table 69:Middle East and Africa Veterinary Lyme Disease Vaccines Sales by Application (2020-2025) & (k doses)
Table 70:Middle East and Africa Veterinary Lyme Disease Vaccines Sales by Application (2020-2025) & (US$ Million)
Table 71:Zoetis Company Information
Table 72:Zoetis Business Overview
Table 73:Zoetis Veterinary Lyme Disease Vaccines Sales (k doses), Revenue (US$ Million), Price (USD/dose) and Gross Margin (2020-2025)
Table 74:Zoetis Veterinary Lyme Disease Vaccines Product Portfolio
Table 75:Zoetis Recent Development
Table 76:Boehringer Ingelheim Company Information
Table 77:Boehringer Ingelheim Business Overview
Table 78:Boehringer Ingelheim Veterinary Lyme Disease Vaccines Sales (k doses), Revenue (US$ Million), Price (USD/dose) and Gross Margin (2020-2025)
Table 79:Boehringer Ingelheim Veterinary Lyme Disease Vaccines Product Portfolio
Table 80:Boehringer Ingelheim Recent Development
Table 81:Elanco Company Information
Table 82:Elanco Business Overview
Table 83:Elanco Veterinary Lyme Disease Vaccines Sales (k doses), Revenue (US$ Million), Price (USD/dose) and Gross Margin (2020-2025)
Table 84:Elanco Veterinary Lyme Disease Vaccines Product Portfolio
Table 85:Elanco Recent Development
Table 86:Merck Animal Health Company Information
Table 87:Merck Animal Health Business Overview
Table 88:Merck Animal Health Veterinary Lyme Disease Vaccines Sales (k doses), Revenue (US$ Million), Price (USD/dose) and Gross Margin (2020-2025)
Table 89:Merck Animal Health Veterinary Lyme Disease Vaccines Product Portfolio
Table 90:Merck Animal Health Recent Development
Table 91:Bioveta Company Information
Table 92:Bioveta Business Overview
Table 93:Bioveta Veterinary Lyme Disease Vaccines Sales (k doses), Revenue (US$ Million), Price (USD/dose) and Gross Margin (2020-2025)
Table 94:Bioveta Veterinary Lyme Disease Vaccines Product Portfolio
Table 95:Bioveta Recent Development
Table 96:North America Veterinary Lyme Disease Vaccines Market Size Growth Rate (CAGR) by Country (k doses): 2020 VS 2024 VS 2031
Table 97:North America Veterinary Lyme Disease Vaccines Sales by Country (2020-2025) & (k doses)
Table 98:North America Veterinary Lyme Disease Vaccines Sales Market Share by Country (2020-2025)
Table 99:North America Veterinary Lyme Disease Vaccines Sales Forecast by Country (2026-2031) & (k doses)
Table 100:North America Veterinary Lyme Disease Vaccines Sales Market Share Forecast by Country (2026-2031)
Table 101:North America Veterinary Lyme Disease Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2020 VS 2024 VS 2031
Table 102:North America Veterinary Lyme Disease Vaccines Market Size by Country (2020-2025) & (US$ Million)
Table 103:North America Veterinary Lyme Disease Vaccines Market Share by Country (2020-2025)
Table 104:North America Veterinary Lyme Disease Vaccines Market Size Forecast by Country (2026-2031) & (US$ Million)
Table 105:North America Veterinary Lyme Disease Vaccines Market Share Forecast by Country (2026-2031)
Table 106:Europe Veterinary Lyme Disease Vaccines Market Size Growth Rate (CAGR) by Country (k doses): 2020 VS 2024 VS 2031
Table 107:Europe Veterinary Lyme Disease Vaccines Sales by Country (2020-2025) & (k doses)
Table 108:Europe Veterinary Lyme Disease Vaccines Sales Market Share by Country (2020-2025)
Table 109:Europe Veterinary Lyme Disease Vaccines Sales Forecast by Country (2026-2031) & (k doses)
Table 110:Europe Veterinary Lyme Disease Vaccines Sales Market Share Forecast by Country (2026-2031)
Table 111:Europe Veterinary Lyme Disease Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2020 VS 2024 VS 2031
Table 112:Europe Veterinary Lyme Disease Vaccines Market Size by Country (2020-2025) & (US$ Million)
Table 113:Europe Veterinary Lyme Disease Vaccines Market Share by Country (2020-2025)
Table 114:Europe Veterinary Lyme Disease Vaccines Market Size Forecast by Country (2026-2031) & (US$ Million)
Table 115:Europe Veterinary Lyme Disease Vaccines Market Share Forecast by Country (2026-2031)
Table 116:Asia-Pacific Veterinary Lyme Disease Vaccines Market Size Growth Rate (CAGR) by Country (k doses): 2020 VS 2024 VS 2031
Table 117:Asia-Pacific Veterinary Lyme Disease Vaccines Sales by Country (2020-2025) & (k doses)
Table 118:Asia-Pacific Veterinary Lyme Disease Vaccines Sales Market Share by Country (2020-2025)
Table 119:Asia-Pacific Veterinary Lyme Disease Vaccines Sales Forecast by Country (2026-2031) & (k doses)
Table 120:Asia-Pacific Veterinary Lyme Disease Vaccines Sales Market Share Forecast by Country (2026-2031)
Table 121:Asia-Pacific Veterinary Lyme Disease Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2020 VS 2024 VS 2031
Table 122:Asia-Pacific Veterinary Lyme Disease Vaccines Market Size by Country (2020-2025) & (US$ Million)
Table 123:Asia-Pacific Veterinary Lyme Disease Vaccines Market Share by Country (2020-2025)
Table 124:Asia-Pacific Veterinary Lyme Disease Vaccines Market Size Forecast by Country (2026-2031) & (US$ Million)
Table 125:Asia-Pacific Veterinary Lyme Disease Vaccines Market Share Forecast by Country (2026-2031)
Table 126:Latin America Veterinary Lyme Disease Vaccines Market Size Growth Rate (CAGR) by Country (k doses): 2020 VS 2024 VS 2031
Table 127:Latin America Veterinary Lyme Disease Vaccines Sales by Country (2020-2025) & (k doses)
Table 128:Latin America Veterinary Lyme Disease Vaccines Sales Market Share by Country (2020-2025)
Table 129:Latin America Veterinary Lyme Disease Vaccines Sales Forecast by Country (2026-2031) & (k doses)
Table 130:Latin America Veterinary Lyme Disease Vaccines Sales Market Share Forecast by Country (2026-2031)
Table 131:Latin America Veterinary Lyme Disease Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2020 VS 2024 VS 2031
Table 132:Latin America Veterinary Lyme Disease Vaccines Market Size by Country (2020-2025) & (US$ Million)
Table 133:Latin America Veterinary Lyme Disease Vaccines Market Share by Country (2020-2025)
Table 134:Latin America Veterinary Lyme Disease Vaccines Market Size Forecast by Country (2026-2031) & (US$ Million)
Table 135:Latin America Veterinary Lyme Disease Vaccines Market Share Forecast by Country (2026-2031)
Table 136:Middle East and Africa Veterinary Lyme Disease Vaccines Market Size Growth Rate (CAGR) by Country (k doses): 2020 VS 2024 VS 2031
Table 137:Middle East and Africa Veterinary Lyme Disease Vaccines Sales by Country (2020-2025) & (k doses)
Table 138:Middle East and Africa Veterinary Lyme Disease Vaccines Sales Market Share by Country (2020-2025)
Table 139:Middle East and Africa Veterinary Lyme Disease Vaccines Sales Forecast by Country (2026-2031) & (k doses)
Table 140:Middle East and Africa Veterinary Lyme Disease Vaccines Sales Market Share Forecast by Country (2026-2031)
Table 141:Middle East and Africa Veterinary Lyme Disease Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2020 VS 2024 VS 2031
Table 142:Middle East and Africa Veterinary Lyme Disease Vaccines Market Size by Country (2020-2025) & (US$ Million)
Table 143:Middle East and Africa Veterinary Lyme Disease Vaccines Market Share by Country (2020-2025)
Table 144:Middle East and Africa Veterinary Lyme Disease Vaccines Market Size Forecast by Country (2026-2031) & (US$ Million)
Table 145:Middle East and Africa Veterinary Lyme Disease Vaccines Market Share Forecast by Country (2026-2031)
Table 146:Key Raw Materials
Table 147:Raw Materials Key Suppliers
Table 148:Veterinary Lyme Disease Vaccines Distributors List
Table 149:Veterinary Lyme Disease Vaccines Customers List
Table 150:Research Programs/Design for This Report
Table 151:Authors List of This Report
Table 152:Secondary Sources
Table 153:Primary Sources
Figure 1:Veterinary Lyme Disease Vaccines Image
Figure 2:Global Veterinary Lyme Disease Vaccines Market Size (US$ Million), 2020 VS 2024 VS 2031
Figure 3:Global Veterinary Lyme Disease Vaccines Market Size (2020-2031) & (US$ Million)
Figure 4:Global Veterinary Lyme Disease Vaccines Sales (2020-2031) & (k doses)
Figure 5:Recombinant Subunit Vaccines Image
Figure 6:Global Recombinant Subunit Vaccines Sales YoY Growth (2020-2031) & (k doses)
Figure 7:Bacterin Vaccines Image
Figure 8:Global Bacterin Vaccines Sales YoY Growth (2020-2031) & (k doses)
Figure 9:Global Veterinary Lyme Disease Vaccines Market Size Overview by Type (2020-2031) & (US$ Million)
Figure 10:Global Veterinary Lyme Disease Vaccines Market Share by Type 2024 VS 2031
Figure 11:North America Veterinary Lyme Disease Vaccines Sales Market Share in Volume by Type in 2024
Figure 12:North America Veterinary Lyme Disease Vaccines Sales Market Share in Value by Type in 2024
Figure 13:Europe Veterinary Lyme Disease Vaccines Sales Market Share in Volume by Type in 2024
Figure 14:Europe Veterinary Lyme Disease Vaccines Sales Market Share in Value by Type in 2024
Figure 15:Asia-Pacific Veterinary Lyme Disease Vaccines Sales Market Share in Volume by Type in 2024
Figure 16:Asia-Pacific Veterinary Lyme Disease Vaccines Sales Market Share in Value by Type in 2024
Figure 17:Latin America Veterinary Lyme Disease Vaccines Sales Market Share in Volume by Type in 2024
Figure 18:Latin America Veterinary Lyme Disease Vaccines Sales Market Share in Value by Type in 2024
Figure 19:Middle East and Africa Veterinary Lyme Disease Vaccines Sales Market Share in Volume by Type in 2024
Figure 20:Middle East and Africa Veterinary Lyme Disease Vaccines Sales Market Share in Value by Type in 2024
Figure 21:Global Top 5 and 10 Veterinary Lyme Disease Vaccines Players Market Share by Revenue in 2024
Figure 22:Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 23:Canine Image
Figure 24:Global Canine Sales YoY Growth (2020-2031) & (k doses)
Figure 25:Feline Image
Figure 26:Global Feline Sales YoY Growth (2020-2031) & (k doses)
Figure 27:Global Veterinary Lyme Disease Vaccines Market Size Overview by Application (2020-2031) & (US$ Million)
Figure 28:Global Veterinary Lyme Disease Vaccines Market Share by Application 2024 VS 2031
Figure 29:North America Veterinary Lyme Disease Vaccines Sales Market Share in Volume by Application in 2024
Figure 30:North America Veterinary Lyme Disease Vaccines Sales Market Share in Value by Application in 2024
Figure 31:Europe Veterinary Lyme Disease Vaccines Sales Market Share in Volume by Application in 2024
Figure 32:Europe Veterinary Lyme Disease Vaccines Sales Market Share in Value by Application in 2024
Figure 33:Asia-Pacific Veterinary Lyme Disease Vaccines Sales Market Share in Volume by Application in 2024
Figure 34:Asia-Pacific Veterinary Lyme Disease Vaccines Sales Market Share in Value by Application in 2024
Figure 35:Latin America Veterinary Lyme Disease Vaccines Sales Market Share in Volume by Application in 2024
Figure 36:Latin America Veterinary Lyme Disease Vaccines Sales Market Share in Value by Application in 2024
Figure 37:Middle East and Africa Veterinary Lyme Disease Vaccines Sales Market Share in Volume by Application in 2024
Figure 38:Middle East and Africa Veterinary Lyme Disease Vaccines Sales Market Share in Value by Application in 2024
Figure 39:North America Veterinary Lyme Disease Vaccines Sales by Country: 2020 VS 2024 VS 2031 (k doses)
Figure 40:North America Veterinary Lyme Disease Vaccines Sales Share by Country: 2020 VS 2024 VS 2031
Figure 41:North America Veterinary Lyme Disease Vaccines Market Size by Country: 2020 VS 2024 VS 2031 (US$ Million)
Figure 42:North America Veterinary Lyme Disease Vaccines Market Share by Country: 2020 VS 2024 VS 2031
Figure 43:Europe Veterinary Lyme Disease Vaccines Sales by Country: 2020 VS 2024 VS 2031 (k doses)
Figure 44:Europe Veterinary Lyme Disease Vaccines Sales Share by Country: 2020 VS 2024 VS 2031
Figure 45:Europe Veterinary Lyme Disease Vaccines Market Size by Country: 2020 VS 2024 VS 2031 (US$ Million)
Figure 46:Europe Veterinary Lyme Disease Vaccines Market Share by Country: 2020 VS 2024 VS 2031
Figure 47:Asia-Pacific Veterinary Lyme Disease Vaccines Sales by Country: 2020 VS 2024 VS 2031 (k doses)
Figure 48:Asia-Pacific Veterinary Lyme Disease Vaccines Sales Share by Country: 2020 VS 2024 VS 2031
Figure 49:Asia-Pacific Veterinary Lyme Disease Vaccines Market Size by Country: 2020 VS 2024 VS 2031 (US$ Million)
Figure 50:Asia-Pacific Veterinary Lyme Disease Vaccines Market Share by Country: 2020 VS 2024 VS 2031
Figure 51:Latin America Veterinary Lyme Disease Vaccines Sales by Country: 2020 VS 2024 VS 2031 (k doses)
Figure 52:Latin America Veterinary Lyme Disease Vaccines Sales Share by Country: 2020 VS 2024 VS 2031
Figure 53:Latin America Veterinary Lyme Disease Vaccines Market Size by Country: 2020 VS 2024 VS 2031 (US$ Million)
Figure 54:Latin America Veterinary Lyme Disease Vaccines Market Share by Country: 2020 VS 2024 VS 2031
Figure 55:Middle East and Africa Veterinary Lyme Disease Vaccines Sales by Country: 2020 VS 2024 VS 2031 (k doses)
Figure 56:Middle East and Africa Veterinary Lyme Disease Vaccines Sales Share by Country: 2020 VS 2024 VS 2031
Figure 57:Middle East and Africa Veterinary Lyme Disease Vaccines Market Size by Country: 2020 VS 2024 VS 2031 (US$ Million)
Figure 58:Middle East and Africa Veterinary Lyme Disease Vaccines Market Share by Country: 2020 VS 2024 VS 2031
Figure 59:Veterinary Lyme Disease Vaccines Value Chain
Figure 60:Key Raw Materials Price
Figure 61:Manufacturing Cost Structure
Figure 62:Veterinary Lyme Disease Vaccines Production Mode & Process
Figure 63:Direct Comparison with Distribution Share
Figure 64:Distributors Profiles
Figure 65:Years Considered
Figure 66:Research Process
Figure 67:Key Executives Interviewed

Request a Sample

Sample excerpt is intended to facilitate an informed purchase decision. Its purpose is not to offer free information or act as a substitute for the comprehensive product. In order to tailor the sample to your specific requirements, we will reach out to you to gather more details about your criteria.

Report Cover

Pharma & Healthcare

Global Veterinary Lyme Disease Vaccines Industry Growth and Trends Forecast to 2031

0| 0 Reviews

Pages: 97

Complete Your Request

Select Country
Phone

Customer reviews

  • starstarstarstarstar
  • 0 out of 5
  • 0 Reviews

5

star rating

4

star rating

3

star rating

2

star rating

1

star rating

No Rating Review Exist.

Write Review
  • starstarstarstarstar

Suggested Report

View More

No data found.